Sponsor Directory

AbbVie clinical trials

Sponsor pages show live ClinicalTrials.gov search results and objective aggregate stats only. They do not describe sponsor quality, reputation, or expected outcomes.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 4:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

816

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Psoriasis
Interventions: Risankizumab-Rzaa, Punch biopsies of the skin at baseline visit, Punch biopsies of the skin at week 28 visit; Drug · Procedure
Lead sponsor: Jaehwan Kim; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 3
States / cities: Sacramento, California • New York, New York

Conditions: Advanced High-Grade Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancers
Interventions: Mirvetuximab Soravtansine; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 7
States / cities: Sarasota, Florida • Edgewood, Kentucky • Lexington, Kentucky + 4 more

Conditions: Diffuse Large B-cell Lymphoma
Interventions: Epcoritamab, Investigator's Choice Chemotherapy; Biological · Drug
Lead sponsor: Genmab; Industry
Eligibility: 18 Years and older
Enrollment: 483 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 15
States / cities: Indianapolis, Indiana • Lexington, Kentucky • Jackson, Michigan + 10 more

Conditions: Facial Contouring
Interventions: OnabotulinumtoxinA, JUVÉDERM, CoolSculpting Elite System, SkinMedica Products, KYBELLA; Drug · Device · Other
Lead sponsor: AbbVie; Industry
Eligibility: 22 Years to 65 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 10
States / cities: Redondo Beach, California • Vista, California • Washington D.C., District of Columbia + 7 more

Conditions: Follicular Lymphoma, Low Grade Non-Hodgkin's Lymphoma, Adult
Interventions: Epcoritamab, Rituximab; Drug
Lead sponsor: Reid Merryman, MD; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 6
States / cities: Boston, Massachusetts • New York, New York • Rochester, New York + 2 more

Conditions: Open-angle Glaucoma, Ocular Hypertension
Interventions: AGN-193408 SR, Lumigan, Sham Administration, Lumigan Vehicle; Drug · Other
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 42
States / cities: Sun City, Arizona • Glendale, California • Inglewood, California + 38 more

Conditions: Prurigo Nodularis
Interventions: Upadacitinib; Drug
Lead sponsor: Psoriasis Treatment Center of Central New Jersey; Other
Eligibility: 18 Years to 64 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: East Windsor, New Jersey

Conditions: Myelodysplastic Syndrome, Recurrent Myelodysplastic Syndrome, Refractory Myelodysplastic Syndrome
Interventions: Navitoclax, Venetoclax, Decitabine, Bone Marrow Biopsy, Biospecimen Collection, Laboratory Biomarker Analysis, Quality-of-Life Assessment; Biological · Drug · Procedure + 1 more
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Migraine
Interventions: MEDI0618, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 488 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 16
States / cities: Birmingham, Alabama • Huntsville, Alabama • La Jolla, California + 13 more

Conditions: Functional Constipation (FC), Chronic Idiopathic Constipation (CIC)
Interventions: Placebo for Linaclotide, Linaclotide; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 2 Years to 5 Years
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 38
States / cities: Foley, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 33 more

Conditions: Ulcerative Colitis
Interventions: Upadacitinib; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 20
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Corona, California + 16 more

Conditions: Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Non-Hodgkin's Lymphoma, Acute Lymphoblastic Leukemia, Cancer
Interventions: Venetoclax; Drug
Lead sponsor: AbbVie; Industry
Eligibility: Not listed
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 7
States / cities: Tucson, Arizona • Los Angeles, California • Harvey, Illinois + 4 more

About this AbbVie sponsor directory page

What this page lists: U.S. ClinicalTrials.gov public records where AbbVie is the lead sponsor, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by condition, intervention, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within AbbVie trials.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, sponsor quality scoring, ranking of trials, or AI-generated medical summaries.

AbbVie clinical trials

Filter and sort this sponsor

Live official records

Risankizumab Long-term Remission Study

A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine

A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)

A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVÉDERM® Products, KYBELLA, CoolSculpting Elite and SkinMedica Products

Epcoritamab and Rituximab for First-line Follicular Lymphoma

AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension

Upadacitinib for Prurigo Nodularis

Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome

A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine

A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation

Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.

An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial

About this AbbVie sponsor directory page